| Title |
Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study
|
|---|---|
| Published in |
Drug Design, Development and Therapy, February 2014
|
| DOI | 10.2147/dddt.s54064 |
| Pubmed ID | |
| Authors |
Jochen G Mainz, Katja Schädlich, Claudia Schien, Ruth Michl, Petra Schelhorn-Neise, Assen Koitschev, Christiane Koitschev, Peter M Keller, Joachim Riethmüller, Baerbel Wiedemann, James F Beck |
| Abstract |
In cystic fibrosis (CF), the paranasal sinuses are sites of first and persistent colonization by pathogens such as Pseudomonas aeruginosa. Pathogens subsequently descend to the lower airways, with P. aeruginosa remaining the primary cause of premature death in patients with the inherited disease. Unlike conventional aerosols, vibrating aerosols applied with the PARI Sinus™ nebulizer deposit drugs into the paranasal sinuses. This trial assessed the effects of vibrating sinonasal inhalation of the antibiotic tobramycin in CF patients positive for P. aeruginosa in nasal lavage. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 1% |
| Unknown | 79 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 19% |
| Student > Bachelor | 12 | 15% |
| Other | 7 | 9% |
| Student > Ph. D. Student | 6 | 8% |
| Student > Master | 6 | 8% |
| Other | 13 | 16% |
| Unknown | 21 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Psychology | 3 | 4% |
| Agricultural and Biological Sciences | 3 | 4% |
| Nursing and Health Professions | 3 | 4% |
| Other | 10 | 13% |
| Unknown | 22 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 July 2022.
All research outputs
#6,754,036
of 25,374,647 outputs
Outputs from Drug Design, Development and Therapy
#427
of 2,268 outputs
Outputs of similar age
#73,440
of 322,718 outputs
Outputs of similar age from Drug Design, Development and Therapy
#5
of 23 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,718 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.